Good outlook for Novozymes after eventful 2013

Published: 27-Jan-2014
Ingredients Finance

Strong increase in sales of products for the manufacture of pharmaceuticals


Danish enzymes producer Novozymes expects strong sales and earnings in 2014, after what Peder Holk Nielsen, President and CEO, described as an 'eventful 2013'.

Organic sales growth in 2013 was up 7% to DKK11.7bn (US$2.14bn), EBIT grew by 6% to DKK2.9bn and net profit by 9% to DKK2.2bn.

Sales to the Technical & Pharma Industries increased by 7% to DKK757m, driven by a strong increase in sales for the manufacture of pharmaceutical products, particularly in Europe, the Middle East and Africa.

Holk Nielsen said: 'We delivered a good finish to the year and ended at the high end of our guided ranges for sales growth and above that for earnings. The outlook for 2014 is positive. We expect that our diversified growth platform will enable us to deliver good sales and EBIT growth.'

  • Companies:
  • Novozymes
See more

You may also like

Finance

Novo companies announce enzyme collaboration for biopharmaceuticals

Read more
Enzymes used in biopharmaceutical processing make up a small part of the 15bn DKK ($2.3bn) market for specialty enzymes, with yearly expected growth rates in the high-single digits

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic (PK) half-lives or narrow therapeutic indices. This is becoming a reality with modified-release (MR) oral delivery systems such as hydrophilic matrix tablets
  4. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  5. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Novo companies announce enzyme collaboration for biopharmaceuticals

Enzymes used in biopharmaceutical processing make up a small part of the 15bn DKK ($2.3bn) market for specialty enzymes, with yearly expected growth rates in the high-single digits
Ingredients

Novozymes reports a good year in 2014

Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%
Finance

Novozymes reports 4% increase in sales in Q1

Biopharma sales rise by 22%
Ingredients

Novozymes’ agreement with GSK brings payback closer

GSK is seeking approval in Europe for diabetes drug Eperzan
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Safe, consistent and sustainable hyaluronic acid

Hyaluronic acid (HA) is a naturally occurring polysaccharide ubiquitous in nature, which is distributed widely throughout connective, epithelial and neural tissues in the human body. Due to its intrinsic biocompatibility, biodegradability and diverse biological functions, HA is widely used in medical devices and pharmaceutical applications. In response to concerns surrounding the purity of many sources of HA, a <i>Bacillus subtilis</i>-based fermentation process has been developed by Novozymes Biopharma.
Ingredients

Novozymes Biopharma aligns recombinant human albumin portfolio with new brand name

Portfolio will bring together rAlbumin product line with introduction of new brand names Recombumin Alpha and Recombumin Prime
Ingredients

Enzymes cut industrial emissions and resource use

Comprehensive scientific review of existing studies shows enzyme technology is a promising means of moving towards cleaner industrial production
Subscribe now